SCoRS is currently being used as a co-primary endpoint in several international phase 2 and phase 3 trials assessing cognitive treatment change in schizophrenia, and has been permitted by the FDA for pivotal registration trials. SCoRS is a 20-item measure that requires 15 minutes to complete. It has excellent test-retest reliability, strong relation to cognitive performance, and proven sensitivity to treatment.

Watch Dr. Keefe as he highlights how SCoRS can help evaluate the ties between cognitive impairment and poor functioning.

SCoRs – Schizophrenia Cognition Rating Scale from NeuroCog Trials

Learn more about SCoRS on Wikipedia